Published in final edited form as:

Alzheimers Dement. 2008 January ; 4(Supplement 1): s153–s168.

Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses

Mehmet Cansev^{a,b}, Richard J. Wurtman^{a,*}, Toshimasa Sakamoto^a, and Ismail H. Ulus^{a,b}

^a*Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences, Cambridge MA, 02139, USA*

^b*Uludag University School of Medicine, Department of Pharmacology and Clinical Pharmacology, Bursa 16059, Turkey*

Abstract

Although cognitive performance in humans and experimental animals can be improved by administering the omega-3 fatty acid docosahexaenoic acid (DHA), the neurochemical mechanisms underlying this effect remain uncertain. In general, nutrients or drugs that modify brain function or behavior do so by affecting synaptic transmission, usually by changing the quantities of particular neurotransmitters present within synaptic clefts or by acting directly on neurotransmitter receptors or signal-transduction molecules. We find that DHA also affects synaptic transmission in mammalian brain: Brain cells of gerbils or rats receiving this fatty acid manifest increased levels of phosphatides and of specific pre- or post-synaptic proteins. They also exhibit increased numbers of dendritic spines on postsynaptic neurons. These actions are markedly enhanced in animals that have also received the other two circulating precursors for phosphatidylcholine – uridine (which gives rise to brain UTP and CTP), and choline (which gives rise to phosphocholine). The actions of DHA are reproduced by eicosapentaenoic acid (EPA), another omega-3 compound, but not by the omega-6 fatty acid arachidonic acid (AA). Administration of circulating phosphatide precursors can also increase neurotransmitter release (acetylcholine; dopamine) and affect animal behavior. Conceivably, this treatment might have use in patients with the synaptic loss that characterizes Alzheimer's disease or other neurodegenerative diseases, or occurs after stroke or brain injury.

1. Introduction

While theories abound as to the precise pathologic mechanisms which diminish the numbers of brain synapses in patients with Alzheimer's Disease, there seems to be little doubt that these reductions do invariably occur, and that they are a major factor causing patients to develop cognitive disturbances [1]. If it were possible to cause the surviving neurons in damaged brain regions to make more or larger synapses, would this restore neurotransmission, and would it ameliorate the behavioral symptoms of the disease? It has never been possible to test this hypothesis, because no method has been known which reliably increases synaptic number or size. But now a treatment has been identified which increases the quantities of synaptic membrane in [2], and the numbers of dendritic spines on [3] hippocampal cells of normal animals. Although it remains to be determined whether this treatment also affects synapses in brains of normal humans, much less patients with Alzheimer's Disease, the compounds it uses

*Corresponding Author: Richard J. Wurtman, MD MIT, 43 Vassar St., Building 46, Room 5023B Cambridge MA, 02139 Phone: 617-253-6731 Fax: 617-253-6882

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

all occur normally in the blood and apparently are benign. Hence, it may be useful to determine whether their administration is beneficial to patients with Alzheimer's Disease.

The circulating compounds involved are three essential precursors needed to synthesize phosphatidylcholine (PC), the major phosphatide in neuronal membranes [4], as well as the other principal phosphatides, i.e. the polyunsaturated omega-3 fatty acid docosahexaenoic acid (DHA); a uridine source; and a choline source. As described below each of these compounds can be limiting in controlling the overall rate of PC synthesis (because their levels in brain are insufficient to saturate the brain enzymes that catalyze the reactions involved in PC synthesis), and the effects of giving all three together tend to be greater than the summed effects of giving each alone. Uridine may also promote membrane synthesis via the activation of P2Y receptors by its fully phosphorylated product UTP [5], and DHA's effects may also involve alternative sites of action [6], including for example activation of brain proteins serving as receptors [7]. Perhaps surprisingly, when the three precursors are administered chronically not only do brain levels of phosphatides – a lipid moiety – rise but also those of certain pre- and post-synaptic proteins [2,8], and major structural changes occur – an increase in the number of dendritic spines [3].

This article summarizes available information on the biochemical mechanisms that mediate the effects on synaptic membrane of exogenous DHA, uridine, and choline, and on the known consequences of these effects. It also provides a rationale for testing these compounds to treat Alzheimer's Disease or other diseases characterized by synaptic loss.

2. Biosynthesis of Membrane Phosphatides

All cells utilize DHA and other fatty acids, uridine, and choline to form the phosphatide subunits (e.g. PC) (Figure 1) which, when aggregated, constitute the major components of their membranes. PC, the principal such subunit in brain, which is synthesized from these precursors by the CDP-choline cycle or “Kennedy Cycle” [9] (Figure 2), also provides the phosphocholine moiety needed to synthesize sphingomyelin, the other major choline-containing brain phospholipid. The phosphatide phosphatidylethanolamine (PE) likewise is synthesized via the Kennedy Cycle, utilizing ethanolamine instead of choline, while phosphatidylserine (PS), the third major structural phosphatide, is produced by exchanging a serine molecule for the choline in PC or the ethanolamine in PE [4].

The CDP-choline cycle involves three sequential enzymatic reactions (Fig. 2). In the first, catalyzed by choline kinase (CK), a monophosphate is transferred from ATP to the hydroxyl oxygen of the choline, yielding phosphocholine. The second, catalyzed by CTP:phosphocholine cytidyl transferase (CT), transfers cytidylmonophosphate (CMP) from cytidine-5'-triphosphate (CTP) to the phosphorus of phosphocholine, yielding cytidyldiphosphocholine (also known as CDP-choline or as citicoline). As discussed below, much of the CTP that the human brain uses for this reaction derives from circulating uridine [10]. The third and last reaction, catalyzed by CDP-choline:1,2-Diacylglycerol choline phosphotransferase (CPT), bonds the phosphocholine of CDPcholine to the hydroxyl group on the 3- carbon of diacylglycerol (DAG), yielding the PC. All three PC precursors must be obtained by brain entirely or in large part from the circulation, and because the PC-synthesizing enzymes that act on all three have low affinities for them, blood levels of all three can affect the overall rate of PC synthesis [2,11].

Thus, choline administration increases brain phosphocholine levels in rats [12] and humans [13], because CK's K_m for choline (2.6 mM [14]) is much higher than usual brain choline levels (30-60 μ M) [15-17]. Most commonly the second, CT-catalyzed reaction is most rate-limiting in PC synthesis, either because not all of the CT enzyme is fully activated by being attached to a cellular membrane [18] or because local CTP concentrations are insufficient to

saturate the CT [17]. Thus, when brain CTP levels are increased by giving animals uridine [11], CTP's circulating precursor in human blood [10], PC synthesis is accelerated [11]. The activity of CPT and the extent to which this enzyme is saturated with DAG can also control the overall rate of PC synthesis, as has been demonstrated in, for example, permeabilized Hela cells exposed to glycerol-3-phosphate and acyl-CoA [19], or in PC12 cells extending neurites following exposure to the nerve growth factor (NGF) [20]: In PC-12 cells, NGF increased DAG levels five-fold, CPT activity by 70%, and the incorporation of choline into PC by two-fold. DAG species containing DHA or other PUFA on the middle carbon apparently are preferentially utilized for phosphatide synthesis as opposed to triglyceride synthesis [21]. (This does not explain, of course, why giving DHA, thereby presumably increasing, at least transiently, the proportions of PC molecules that contain this PUFA, would also increase the absolute levels of PC in a cell, e.g. in Table 1).

If rodents are given a standard diet supplemented with choline and uridine (as its monophosphate, UMP) and, also by gavage, DHA, brain PC synthesis rapidly increases [2, 11], and absolute levels of PC per cell (DNA) or per mg protein increase substantially (e.g., by 40-50% after several weeks of daily treatment [2] (Table 1). This treatment also increases the levels of each of the other principal membrane phosphatides (Table 1), as well as the levels of particular proteins known to be localized within presynaptic and postsynaptic membranes (for example synapsin-1 [22], PSD-95 [23] and syntaxin-3 [7]), but not a ubiquitously-distributed brain protein, β -tubulin (Figure 3) [2,8]. As described below, treatment with DHA, UMP and choline also promotes the formation of dendritic spines in adult gerbil hippocampus [3] (see section 6); and improves hippocampus-dependent cognitive behaviors in rats reared in a socially-deprived environment [24] (see section 7). Thus, the production and levels of brain phosphatides and synaptic proteins are found to depend to a surprising extent on blood levels of PC's three circulating precursors. Providing supplemental UMP or DHA without the other can also increase brain phosphatide levels, but by less than when all three precursors are presented. (Choline is included in all of the test diets).

In studies designed to affirm that the increases in brain phosphatide levels caused by giving DHA, with or without UMP, reflect actual increases in phosphatide synthesis (and not, for example, inhibition of phosphatide degradation), brain levels of CDP-choline and CDP-ethanolamine, the immediate precursors of PC and PE, also were measured. It was postulated that if DHA acted by generating more DHA-containing DAG, and if this compound then combined with endogenous CDP-choline or CDP-ethanolamine to form additional PC or PE, then DHA administration would concurrently reduce brain CDP-choline or CDP-ethanolamine while increasing brain levels of their PC products and PE. This expectation was confirmed [2]: among animals receiving either DHA alone, or DHA plus UMP: CDP-choline and CDP-ethanolamine levels fell significantly while those of PC and PE rose (Figure 4).

3. Properties of the enzymes that mediate brain phosphatide synthesis

The ability of each of the three circulating phosphatide precursors to affect the rate of phosphatide synthesis results principally from the low affinities of these enzymes for their substrates. This unusual property is described below.

3.1. Choline Kinase

The synthesis of PC (Figure 2) is initiated by the phosphorylation of choline, in which CK (EC 2.7.1.32) catalyzes the transfer of a monophosphate group from ATP to the hydroxyl oxygen of the choline. In some neurons choline is also used, of course, to synthesize the neurotransmitter acetylcholine (ACh), the enzyme choline acetyltransferase (ChAT) transferring an acetyl group from acetyl-CoA to the hydroxyl oxygen of the choline. Like CK, ChAT has a very low affinity for its choline substrate [25,26]. The K_m 's of these enzymes in

brain (which, of course, describe the choline concentrations at which the enzymes operate at only half-maximal velocity) are reportedly 2.6 mM [14] and 540 μ M [27], respectively, whereas brain choline levels are only about 30-60 μ M [15-17]. Hence, the syntheses of both phosphocholine and ACh are highly responsive to treatments which raise or lower brain choline levels.

The ability of choline administration to increase brain phosphocholine levels was first noted in 1982 [12] and its similar effect on ACh in 1975 [28,29]. It had previously been shown that the production of another brain neurotransmitter, serotonin, was increased among animals receiving physiologic doses of its circulating precursor, tryptophan [30,31]. This was shown to be because tryptophan hydroxylase, the enzyme that determines the overall rate at which tryptophan is converted to serotonin, has a very low affinity for this substrate. Inasmuch as the affinities for choline of CK and ChAT, measured *in vitro*, were also known to be low relative to choline availability, it seemed reasonable to enquire as to whether giving choline could also increase phosphocholine or ACh synthesis.

Even though brain choline concentrations shared with those of tryptophan the ability to control the rates at which the precursor is used to synthesize a neurotransmitter, synthesis, choline and tryptophan differed in an important respect: Both are used by certain neurons for two purposes - tryptophan for conversion to serotonin and incorporation into proteins, and choline for conversion to ACh and incorporation into phospholipids – however in the case of tryptophan these two processes are segregated into different parts of the neuron, the nerve terminal and perikaryon, whereas for choline both can take place within the nerve terminal (because that structure contains both ChAT and CK). Hence, the acetylation and the phosphorylation of choline sometimes compete for available substrate [32,33]: When cholinergic neurons are forced to fire frequently and maintain the rapid release of ACh, choline's incorporation into PC decreases [32] and the breakdown of membrane PC increases (“autocannibalism”), both processes liberating additional choline for ACh synthesis [34-36]. However, when the utilization of choline to form PC is increased (by providing supplemental uridine and an omega-3 fatty acid, as described above), ACh synthesis is not diminished, probably because so little choline is used for phosphatide formation relative to the amount used to produce ACh [33].

3.2. CTP:phosphocholine cytidyltransferase

CTP:phosphocholine cytidyltransferase (CT; EC 2.7.7.15) catalyzes the condensation of CTP and phosphocholine to form CDP-choline (Figure 2). CT is present in both the soluble and particulate fractions of the cell [37]; the cytosolic form is reportedly inactive and the membrane-bound form active [18,38]. Increases in the association of CT with membranes reportedly correlate with increases in CT activity and in the net synthesis of PC *in vitro* [39-41]. Some other lipids (e.g. PS) [42] and DAG [39,43] also stimulate the translocation of CT from the cytosol to membranes *in vitro*, thereby activating the enzyme [44]. The phosphorylation state of CT affects its net activity [45], as does its substrate saturation with CTP and perhaps with phosphocholine. The K_m 's of CT for CTP and phosphocholine in brains of laboratory rodents and humans are reportedly 1-1.3 mM and 0.30-0.31 mM [17,46], respectively, while brain levels of these compounds are only 70-110 μ M [11,47,48] and 0.32-0.69 mM [12,16,49] respectively. Hence, brain CT normally is highly unsaturated with CTP, and only about half-saturated with phosphocholine *in vivo*, suggesting that its degrees of substrate-saturation, particularly with CTP, exert important limiting roles in PC synthesis. In fact, treatments that increase cellular CTP (e.g. administration of a uridine or cytidine source) have been shown to enhance CDP-choline and PC synthesis in poliovirus-infected HeLa cells [50]; undifferentiated PC12 cells [51,52]; slices of rat corpus striatum [53]; and gerbil brain *in vivo* [11].

3.3. CDP-choline:1,2-diacylglycerol cholinephosphotransferase

CDP-choline:1,2-diacylglycerol cholinephosphotransferase (CPT; EC 2.7.8.2) catalyzes the final reaction in the Kennedy cycle; it transfers the phosphocholine moiety from CDP-choline to DAG, thus yielding PC (Figure 2). CPT, an integral membrane protein, is present primarily in the endoplasmic reticulum [54]. The enzyme protein has been solubilized and partially purified from microsomes of rat liver [55,56], rat brain [57] and hamster liver [58]. A human cDNA has been isolated which codes for an enzyme with both cholinephosphotransferase and ethanolamine-phosphotransferase (EPT) activities (hCEPT1 [59]), and a different human cDNA has also been isolated the product of which exhibits only cholinephosphotransferase-specific activity (hCPT1; [60]). CPT may be a reversible enzyme, synthesizing CDP-choline from PC and CMP in microsomal preparations from liver [61,62] or brain [63-65].

The choline phosphotransferase reaction also is unsaturated with the enzyme's substrates: Its K_m values for CDP-choline and DAG in rat liver are 200 μM and 150 μM [66] respectively, while the concentrations of these compounds in liver are approximately 40 μM [67] and 300 μM [68]. (A DAG concentration of at least 1000 μM thus would probably be needed to saturate the enzyme). Brain CDP-choline and DAG levels are even lower, i.e., about 10-30 μM [11, 69] and 75 μM [48], respectively. Levels of cellular DAG have been shown to limit PC synthesis in permeabilized HeLa cells [19], cultured rat hepatocytes [70], and PC12 cells (described above) [11]. None of these studies distinguished between the enzyme which acts on both choline and ethanolamine (PECT1) and the enzyme that acts only on choline (PCT1). A more recent report, using cloning and expression methods, described the K_m of human PECT1 for CDP-choline as being 36 μM [71], which would probably still be too high for it to be saturated with this substrate in brain. The K_m of PCT for its substrates might also be affected by the fatty acid composition of the DAG molecule [72], however, no data are available demonstrating that the fatty acids (e.g., DHA) which are most able to promote PC synthesis [73] do so because they selectively enhance cellular levels of DAG species which are preferentially bound to or acted on by CPT.

3.4. Uptake of uridine into brain and its conversion to UTP and CTP

Since circulating uridine elevates brain CTP levels, thus modulating DHA's effects on the formation of synaptic membrane, the enzymes and uptake proteins that mediate blood uridine's effect on brain CTP are discussed here.

Uridine and cytidine are transported across cell membranes, including the BBB, via two families of transport proteins, i.e. the Na^+ -independent, low-affinity, equilibrative transporters (ENT1 and ENT2) [74] and the Na^+ -dependent, high-affinity, concentrative (CNT1, CNT2, and CNT3) [75] nucleoside transporters [76]. The two ENT proteins, which transport uridine and cytidine with similar affinities, have been cloned from rat [77] and mouse [78]. Inasmuch as their K_m values for the pyrimidines are in the high micromolar range (100-800 μM [79]) they probably mediate BBB pyrimidine uptake only when plasma levels of uridine and cytidine have been elevated experimentally. In contrast, CNT2, which transports both the pyrimidine uridine and such purines as adenosine, probably do mediate uridine transport across the BBB under physiologic conditions. K_m values for the binding of uridine and adenosine to this protein (which has been cloned from rat BBB [80]) are in the low micromolar range (9-40 μM in kidney, intestine, spleen, liver, macrophage and monocytes [81]), while plasma uridine levels are subsaturating, i.e., 0.9-3.9 μM in rats [82]; 3.1-4.9 μM in humans [82]; and around 6.5 μM in gerbils [11]. Cytidine has not been thought to be a substrate for CNT2 [75], however recent studies suggest that CNT2 can also transport this compound, however with a much lower affinity than that for uridine [83-85].

It should be noted that, while both of the pyrimidines, uridine and cytidine, are present in the blood of laboratory rats, human blood contains unmeasurably low quantities of cytidine [82] even among individuals consuming a cytidine source like oral CDP-choline [10]; the cytidine is quantitatively deaminated to uridine in the human liver. Hence, in humans, circulating uridine, and not cytidine, is the precursor of the brain CTP utilized for phosphatide synthesis. Gerbil blood contains both of the pyrimidines, but proportionately less cytidine than blood of rats; hence gerbils are often used as a model for studying the effects of exogenous uridine sources on the human brain [86].

Like other circulating compounds, pyrimidines may also be taken up into brain via the epithelium of the choroid plexus (CP) and the ENT1, ENT2 and CNT3 transporters [74,75]; all of these proteins have been found in CP epithelial cells of rats [77,87,88] and rabbits [89, 90]. However the surface area of BBB is probably 1000 times that of the CP epithelium (i.e., 21.6 m² vs 0.021 m² in humans [91]), hence the BBB is the major locus at which circulating uridine enters the brain.

Uridine and cytidine are converted to their respective nucleotides by successive phosphorylations catalyzed by various kinases. Uridine-cytidine kinase (UCK) (ATP:uridine 5'-phosphotransferase, EC 2.7.1.48) phosphorylates uridine and cytidine to form UMP and CMP, respectively [92-94]. UCK activity is regulated by cellular UTP and CTP levels: At relatively low UTP and CTP levels, uridine taken up into brain cells is phosphorylated, initially by UCK to form uridine nucleotides; at higher UTP and CTP concentrations UCK's activity is inhibited, thus suppressing uridine's phosphorylation [95]. Several different forms of UCK exist, possibly as isoenzymes [96,97]. Humans have two such isoenzymes, UCK1 and UCK2, both of which have been cloned [98,99]. UMP-CMP kinase (UMP-CMPK) (ATP:UMP phosphotransferase, EC 2.7.4.14) [100-102] then converts UMP or CMP to UDP or CDP. These nucleotides in turn are further phosphorylated to UTP and CTP, by nucleoside diphosphate kinases (NDPK) (Nucleoside triphosphate:Nucleoside diphosphate phosphotransferase, EC 2.7.4.6) [103,104]. mRNAs for UCK1 [99] and UMP-CMPK [105] have been described in brain [106,107], as has NDPK activity.

Various interconversions between uridine and cytidine, and between their respective nucleotides, are known to occur in mammalian cells. Cytidine and CMP can be deaminated to uridine and UMP [108], while UTP is aminated to CTP by CTP synthase (UTP:ammonia ligase [ADP-forming], E.C. 6.3.4.2) [109,110]. This enzyme acts by transferring an amide nitrogen from glutamine to the C-4 position of UTP, thus forming CTP [111]. CTP synthase activity has been demonstrated in rat brain [112].

All of the enzymes described above apparently are unsaturated with their respective nucleoside or nucleotide substrates in brain and other tissues. For example, the Km's for uridine and cytidine of UCK prepared from various tissues varied between 33-270 µM [93,94,113,114], and the Km for uridine of recombinant enzyme cloned from mouse brain was 40 µM [115, 116]. Brain uridine and cytidine levels are about 22-46 pmol/mg wet weight [11,117] and 6-43 pmol/mg wet weight [11,118], respectively. Hence, the syntheses of UTP and CTP, and the subsequent syntheses of brain PC and PE via the Kennedy pathway, depend on available levels of their pyrimidine substrates. Indeed, increasing the supply of uridine or cytidine to neuronal cells, in vitro [5,52,53] or in vivo [11,86], enhanced the phosphorylation of uridine and cytidine, and elevated levels of UTP, CTP, and CDP-choline.

4. Availability of DHA and other PUFA to brain cells

The omega-3 polyunsaturated fatty acids DHA and EPA, and the omega-6 fatty acid AA are essential for humans and other animals, and thus must be obtained from the diet either as such or as their also-essential precursors, alpha-linolenic acid (ALA) and linoleic acid (LA).

Although the processes by which circulating PUFAs are taken up into the brain and, subsequently, into brain cells await full characterization, they are thought to include both simple diffusion (also termed “flip-flop”; [119]) and protein-mediated transport [120]. One such transport protein (B-FATP) [121] has been cloned [122]. DHA, EPA and AA are then transported from the brain's ECF into cells, and can be activated to their corresponding CoA species (e.g., docosahexaenoyl-CoA; eicosapentaenoyl-CoA; arachidonoyl-CoA) and acylated to the sn-2 position of DAG [123] to form PUFA-rich DAG species [124,125]. DHA is acylated by a specific acyl-CoA synthetase, Acs16 [126] which exhibits a low affinity for this substrate ($K_m=26 \mu\text{M}$; [127] relative to usual brain DHA levels ($1.3\text{--}1.5 \mu\text{M}$); [128]. Hence, treatments that raise blood DHA levels rapidly increase its uptake into and retention by brain cells.

EPA can be acylated to DAG by the Acyl-CoA synthetase [129] or it can be converted to DHA by brain astrocytes [130], allowing its effects on brain phosphatides and synaptic proteins, described below, to be mediated by DHA itself. Exogenously administered AA, like DHA, is preferentially incorporated into brain phosphatides [131,132], as well as into other lipids, e.g. the plasmalogens [133,134]. AA shares with DHA the ability to activate syntaxin-3 [7], however, as described below, its oral administration to laboratory rodents apparently does not promote synaptic membrane synthesis nor dendritic spine formation.

DHA and AA are major components of brain membrane phospholipids [135]. While AA is widespread throughout the brain and is abundant in phosphatidylinositol (PI) and PC, DHA is concentrated in synaptic regions of gray matter [136] and is especially abundant in PE and PS [137]. In contrast, EPA is found only in trace amounts in brain phosphatides, mostly in PI [138]. No significant differences have been described between the relative proportions of ingested omega-3 and omega-6 PUFAs that actually enter the systemic circulation [139,140]. Moreover, the rates at which radioactively-labeled DHA and AA are taken up into brain and incorporated into phospholipids following systemic injections also are similar [131,141]. (To our knowledge, no study has compared the brain uptake of EPA with that of another PUFA in rodents or humans, however exogenously administered EPA is known to increase brain EPA levels in vivo [142]). On the other hand, the half-lives of the omega-3 PUFAs in the blood (20 ± 5.2 hours for DHA and 67 ± 14 hours for EPA [143]) are substantially higher than that for AA (3.8 seconds [144]). Similarly, the half-life of DHA in brain PC (22.4 ± 2.9 hours), but not in PI or PE, is much longer than that of AA (3.79 ± 0.12 hours) [145]. Thus, a considerable proportion of AA may be cleared from plasma or oxidized before it is utilized for PC synthesis, or, once incorporated into phosphatides, may be liberated by hydrolysis (mediated by phospholipase A2 [146]), and then oxidized.

It should be noted that the ability of orally-administrated DAG, given daily for several weeks, to increase brain phosphatide levels does not necessarily imply that, concurrent with such increases, the quantities of DHA in the phosphatides, relative to the quantities of other fatty acids, also are increased. Indeed this has not been demonstrated. Conceivably, DHA-rich DAG is preferentially utilized for PC synthesis, but once the DAG-containing PC is formed it is rapidly hydrolyzed to form lyso-PC lacking DHA, then reacylated to PC by addition of a different fatty acid (c.f. [146]).

5. Effects of DHA and other PUFA on synaptic protein and phosphatide levels in gerbils

In experiments designed to compare the effects of administering each of the three PUFAs, DHA, EPA, or AA, on brain phosphatide levels, animals received 300 mg/kg daily by gavage of one of the fatty acids for 4 weeks, and consumed a choline-containing diet that did or did not also contain UMP. Giving DHA without uridine increased PC, PI, PE and PS levels significantly, by 18%, 20%, 22%, and 28% respectively (Table 2), throughout the brain (e.g.

in cortex, striatum, hippocampus, brain stem and cerebellum) (Table 3). Giving EPA also increased brain PE, PS, and PI levels significantly, by 21%, 24% and 27%, respectively (Table 2). In contrast, AA administration failed to affect brain levels of any of the phosphatides (Table 2) [8].

Consuming the UMP-supplemented diet alone increased brain PS and PC levels significantly (by 15% and 16%, respectively) (Table 2) compared with those in control gerbils. Among gerbils receiving both UMP and DHA, brain PC, PE, PS, and PI levels rose significantly by 12%, 26%, 34%, and 38%, respectively (Table 2). Similarly, among gerbils receiving both UMP and EPA, brain PC, PE, PS, and PI levels rose significantly by 13%, 30%, 41% and 56%, respectively (Table 2). In contrast, giving UMP with AA failed to increase levels of any brain phosphatide above those found in gerbils receiving UMP alone (Table 2). Total brain phospholipid levels were also elevated significantly, by 16% and 23%, following treatment with UMP plus DHA, or with UMP plus EPA, respectively (Table 2), but not by treatment with UMP plus AA [8]. Essentially similar results were obtained whether data were expressed per μg DNA or per mg protein (data not shown).

Giving the gerbils, as above, DHA or EPA alone significantly increased brain levels of the postsynaptic density protein PSD-95, by 24% or 28% (Figure 3a1). When this treatment was combined with dietary UMP the observed increases in PSD-95 were 29% or 33% greater than those found after UMP-supplementation alone (Figure 3a). AA failed to affect brain PSD-95 levels, either when given alone or in combination with the UMP-supplemented diet (Figure 3a). Similar to PSD-95, levels of Synapsin-1, a presynaptic vesicular protein, were significantly increased, by 31% or 27% respectively, by DHA or EPA treatment alone (Figure 3b1) or by 33% or 36% when the PUFA was combined with UMP (Figure 3b2). Again, AA failed to affect brain Synapsin-1 levels when given alone or concurrent with a UMP-supplemented diet (Figure 3b).

Also similarly to PSD-95 and Synapsin-1, brain levels of Syntaxin-3, a plasma membrane SNARE (soluble N-thylmaleimidesensitive-factor attachment protein receptor) protein which reportedly mediates the stimulation by PUFAs of neurite outgrowth [7] and exocytosis [147] in cultured cells, were significantly increased in animals receiving DHA or EPA by 29% or 19%, respectively (Figure 3c1), whether or not they also received UMP, but AA was without effect if given alone or in combination with UMP (Figure 3c).

None of the PUFA, given alone or with UMP, changed brain levels of the structural protein β -tubulin, perhaps reflecting its ubiquity in brain; hence, β -tubulin was used as the loading control for Western Blot assays of synaptic proteins (Figure 3d).

The mechanism that allows the omega-3 fatty acids DHA and EPA, but not the omega-6 fatty acid AA to increase synaptic membrane is unclear. As discussed above, exogenously administered AA, like DHA, is preferentially incorporated into brain phosphatides [131,132], as well as into other brain lipids (e.g. the plasmalogens; [133,134], and AA shares with DHA the ability to activate syntaxin-3 in vitro [7].

Mechanisms that could underlie the differential effects of omega-3 and omega-6 PUFAs on membrane synthesis might include, among others, different efficacies for their uptakes into brain or their acylation; different half-lives in the circulation; different affinities for enzymes that control their incorporation into DAG and phosphatides (apparently not the case [8]); differences in the rates at which the PUFAs are removed from phosphatides by deacylation; the differential activation of genes encoding proteins needed for membrane synthesis [148]; or the tendency of AA to be incorporated into phospholipids by the acylation of 1-acyl-2-lysoglycerophospholipids, not via the Kennedy cycle [149].

6. Effects of DHA and other PUFA on dendritic spine formation and synaptogenesis

Dendritic spines are small membranous protrusions extending from post-synaptic dendrites in neurons, most of which form synapses with presynaptic axon terminals. The dendritic spines compartmentalize post-synaptic responses, and their numbers are thought to reflect the numbers of excitatory synapses within regions of the central nervous system [150-152]. Oral supplementation with DHA to adult gerbils increases the number of dendritic spines in the hippocampus, particularly if the animals are also supplemented with UMP [3] (Figure 5). As described above, this treatment also increases the levels of membrane phosphatides and of various pre- and post-synaptic proteins [2]. Oral DHA may thus increase the number of brain synapses, particularly when co-administered with UMP.

Gerbils that received daily doses of DHA for 4 weeks (100 or 300 mg/kg, by gavage) exhibited increased dendritic spine density (i.e. the number of spines per length of dendrite) in CA1 pyramidal neurons (Figure 6); the increases were 12 percent ($p = .04$) with the 100 mg/kg/day dose, and 18 percent ($p < .001$) with the 300 mg/kg/day dose. These effects were amplified when gerbils received both DHA (300 mg/kg/day, by gavage, as above) and UMP (0.5%, via the standard choline-containing diet) for 4 weeks, DHA supplementation alone increasing spine density by 19 percent ($p < .004$; Figure 5) and administration of both precursors did so by 36%, or approximately double the increase produced by DHA alone ($p = .008$) (Figure 5). (Giving UMP alone did not affect dendritic spine density significantly (Figure 5), however, it did increase spine density when all dendritic protrusions were included for statistical analysis, including the filopodia, which are precursor forms of dendritic spines). The effect on dendritic spine density of giving both DHA and UMP was already apparent after 1 week of treatment ($p = .02$), and continued for as long as animals were treated (4 weeks) (Figure 5). DHA plus UMP did not affect the length nor width of individual dendritic spines, only their number.

In the above experiments the increases in hippocampal phospholipids after DHA alone were: PC: 8%; PE: 26%; PS: 75%; and PI: 29% (all $p < .05$ except for PC); and after DHA-plus-UMP were: PC: 28%; PE: 59%; PS: 160%; and PI: 100% (all $p < .001$ vs. their controls). Comparable increases were noted in the pre- and post-synaptic proteins examined in the contralateral hippocampus of the same animals. Expression levels of PSD-95 [153] and GluR-1 [154,155] are known to be highly associated with the growth of dendritic spines, and also with the intensity of the physiological responses of the post-synaptic neurons. Synapsin-1, on the other hand, is expressed in pre-synaptic terminals, and apparently anchors synaptic vesicles to the actin cytoskeleton for exocytosis or synaptogenesis [156,157]. The increases in PSD-95, Synapsin-1, and the GluR-1 (a subunit of the glutamatergic AMPA receptor) after treatment with DHA alone were 42, 37, and 29 percent (all $p \leq .05$), while the increases after treatment with DHA-plus-UMP were by 44, 57, and 37 percent, respectively (all $p < .01$). Treatment with DHA or with DHA plus UMP also elevated brain levels of actin, a cytoskeletal protein which can directly regulate the morphology of dendritic spines and which is implicated in such manifestations of synaptic plasticity as long-term potentiation (LTP) and depression (LTD) [150-152,155,158]. Actin levels rose by 60 percent after DHA, and by 88 percent in animals receiving DHA plus UMP [159].

In contrast, levels of β -tubulin, a cytoskeletal protein that is not specifically localized within synaptic structures, are unaffected by the treatments [2].

Oral supplementation with AA failed to affect dendritic spine density in the CA1 region of the adult gerbil hippocampus even though, like DHA, AA does affect synaptic plasticity in cultured neurons [160-162]. As described above, AA also failed to affect hippocampal levels of phosphatides or of synaptic proteins [159; Submitted for publication].

The mechanisms through which DHA, with or without uridine, increases dendritic spine formation may also involve presynaptic processes. Results from various model systems indicate that both DHA [7,163,164] and uridine [5,165,166] can promote axonal growth and exocytosis in cultured cells. As mentioned previously, DHA can activate the SNARE protein Syntaxin-3 [7] while uridine, through UTP, can activate P2Y receptors [5], which are expressed in hippocampal neurons [167] and are implicated in pre-synaptic induction of LTP [168]. Formation of dendritic spines and synaptogenesis in mammalian brains can be induced or initiated by pre-synaptic neurons, and this process may involve calcium [150-152,169]. The increases in spine density with DHA and UMP treatment (Figure 5) may thus result from potentiation of presynaptic or postsynaptic mechanisms.

7. Effects of uridine on neurotransmitter release, and of UMP plus DHA on behavior

Consumption by rats of a diet containing uridine (as UMP) and choline can increase dopamine (DA) and ACh levels in, and – as assessed using in vivo microdialysis – their release from, corpus striatum neurons. Apparently no data are available on the effects on neurotransmitter production or release of giving DHA alone or with the other two phosphatide precursors. Dietary supplementation of aged male Fischer 344 rats with 2.5% UMP for 6 weeks, ad libitum, increased the release of striatal DA that was evoked by potassium-induced depolarization from $283 \pm 9\%$ in control rats to $341 \pm 21\%$ in those receiving the UMP ($P<0.05$) [165]. In general, each animal's DA release correlated with its striatal DA content, measured postmortem. The levels of neurofilament-70 and neurofilament-M proteins, two markers of neurite outgrowth, were also increased after UMP treatment, to $182 \pm 25\%$ of control levels for the neurofilament-70 ($P<0.05$) and to $221 \pm 34\%$ ($P<0.01$) for the neurofilament-M [165].

In a similar microdialysis study, ACh release, basally as well as after administration of atropine (a muscarinic antagonist which blocks inhibitory presynaptic cholinergic receptors), was found to be enhanced following UMP consumption. Among aged animals consuming a UMP-containing diet (2.5%, w/w) for 1 or 6 weeks, baseline ACh levels in striatal microdialysates rose from 73 to 148 fmol/min after 1 week of treatment ($P<0.05$), and to 197 fmol/min after 6 weeks ($P<0.05$) [166]. Dietary UMP (0.5%, 1 week) also amplified the increase in ACh release caused by giving atropine (10 μ M, via the artificial CSF); atropine alone increased ACh concentrations from 81 to 386 fmol/min in control rats and from 127 to 680 fmol/min in those consuming UMP ($P<0.05$). Young rats eating the UMP-containing diet exhibited similar responses. These data suggest that giving a uridine source may enhance some cholinergic functions, perhaps by increasing the amount of synaptic membrane, or the quantities of ACh stored in synaptic vesicles.

Additional evidence that treatment with UMP alone or with UMP plus DHA can affect brain neurotransmission comes from a few behavioral studies [24,170]. Among socially-impaired rats DHA (300 mg/kg by gavage) or DHA plus dietary UMP (0.5%) treatment for 4 weeks reversed the deficits in hippocampal-dependent learning and memory performance [24] (Figure 7). Chronic dietary administration of UMP (0.1%) alone for 3 months also ameliorated this impairment among the impoverished rats [170].

8. Conclusions

Brain phosphatide synthesis requires three circulating compounds: DHA, uridine, and choline. Oral administration of these phosphatide precursors to experimental animals increases the levels of phosphatides and synaptic proteins in the brain and per brain cell, as well as the numbers of dendritic spines on hippocampal neurons. AA fails to reproduce these effects of

DHA. If similar increases occur in human brain, giving these compounds to patients with diseases - like Alzheimer's Disease – which cause the loss of brain synapses could be beneficial.

Acknowledgements

Studies in the authors' laboratories described in this review were supported in part by the National Institute of Mental Health (MH-28783) and the Center for Brain Sciences and Metabolism Charitable Trust.

References

1. Selkoe DJ. Alzheimer's disease is a synaptic failure. *Science* 2002;298:789–91. [PubMed: 12399581]
2. Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, Marzloff G. Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. *Brain Res* 2006;1088:83–92. [PubMed: 16631143]
3. Sakamoto, T.; Wurtman, RJ. Increased dendritic spine density in adult gerbil hippocampus following oral UMP and DHA supplementation; 10th International Conference on Alzheimer' Disease and Related Disorders; Madrid, Spain. 2006.
4. Sastry PS. Lipids of nervous tissue: composition and metabolism. *Prog Lipid Res* 1985;24:69–176. [PubMed: 3916238]
5. Pooler AM, Guez DH, Benedictus R, Wurtman RJ. Uridine enhances neurite outgrowth in nerve growth factor-differentiated pheochromocytoma cells. *Neuroscience* 2005;134:207–14. [PubMed: 15939540]
6. Ulus, IH., et al. In Preparation
7. Darios F, Davletov B. Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3. *Nature* 2006;440:813–17. [PubMed: 16598260]
8. Cansev M, Wurtman RJ. Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils. *Neuroscience*. In Press
9. Kennedy EM, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipids. *J Biol Chem* 1956;222:193–214. [PubMed: 13366993]
10. Wurtman RJ, Regan M, Ulus I, Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. *Biochem Pharmacol* 2000;60:989–92. [PubMed: 10974208]
11. Cansev M, Watkins CJ, van der Beek EM, Wurtman RJ. Oral Uridine 5' monophosphate (UMP) increases brain CDP-choline levels in gerbils. *Brain Res* 2005;1058:101–8. [PubMed: 16126180]
12. Millington WR, Wurtman RJ. Choline administration elevates brain phosphorylcholine levels. *J Neurochem* 1982;38:1748–52. [PubMed: 7077335]
13. Babb SM, Ke Y, Lange N, Kaufman MJ, Renshaw PF, Cohen BM. Oral choline increases choline metabolites in human brain. *Psychiatry Res* 2004;130:1–9. [PubMed: 14972364]
14. Spanner S, Ansell GB. Choline kinase and ethanolamine kinase activity in the cytosol of nerve endings from rat forebrain. *Biochem J* 1979;178:753–60. [PubMed: 36885]
15. Stavinocha WB, Weintraub ST. Choline content of rat brain. *Science* 1974;183:964–5. [PubMed: 4810847]
16. Klein J, Gonzales R, Koppen A, Loffelholz K. Free choline and choline metabolites in rat brain and body fluids: sensitive determination and implications for choline supply to the brain. *Neurochem Int* 1993;22:293–300. [PubMed: 8443570]
17. Ross BM, Moszczynska A, Blusztajn JK, Sherwin A, Lozano A, Kish SJ. Phospholipid biosynthetic enzymes in human brain. *Lipids* 1997;32:351–8. [PubMed: 9113621]
18. Vance DE, Pelech SL. Enzyme translocation in the regulation of phosphatidylcholine biosynthesis. *Trends Biochem Sci* 1984;9:17–20.
19. Lim P, Cornell R, Vance DE. The supply of both CDP-choline and diacylglycerol can regulate the rate of phosphatidylcholine synthesis in HeLa cells. *Biochem Cell Biol* 1986;64:692–8. [PubMed: 3756002]
20. Araki W, Wurtman RJ. Control of membrane phosphatidylcholine synthesis by diacylglycerol levels in neuronal cells undergoing neurite outgrowth. *Proc Natl Acad Sci USA* 1997;94:11946–50. [PubMed: 9342342]

21. Marszalek JR, Lodish HF. Docosahexaenoic acid, fatty acid-interacting proteins, and neuronal function: breastmilk and fish are good for you. *Ann Rev Cell Dev Biol* 2005;21:633–57. [PubMed: 16212510]
22. Ferreira A, Rapoport M. The synapsins: beyond the regulation of neurotransmitter release. *Cell Mol Life Sci* 2002;59:589–95. [PubMed: 12022468]
23. Fujita A, Kurachi Y. SAP family proteins. *Biochem Biophys Res Commun* 2000;269:1–6. [PubMed: 10694467]
24. Holguin S, Martinez J, Huang Y, Liu J, Tsang S, Wurtman RJ. UMP and DHA improve impaired memory in socially impoverished rats. *Society for Neuroscience Abstracts*. 2007
25. Hersh LB. Kinetic studies of the choline acetyltransferase reaction using isotope exchange at equilibrium. *J Biol Chem* 1982;257:12820–34. [PubMed: 6752141]
26. Tucek S. The synthesis of acetylcholine: Twenty years of progress. *Prog Brain Res* 1990;84:467–77. [PubMed: 2267316]
27. Rossier J. Acetyl-coenzyme A and coenzyme A analogues. Their effects on rat brain choline acetyltransferase. *Biochem J* 1977;165:321–6. [PubMed: 921752]
28. Cohen EL, Wurtman RJ. Brain acetylcholine: Increase after systemic choline administration. *Life Sci* 1975;16:1095–102. [PubMed: 1134185]
29. Haubrich DR, Wang PFL, Wedeking PW. Distribution and metabolism of intravenously administered choline[methyl-3H] and synthesis in vivo of acetylcholine in various tissues of guinea pigs. *J Pharmacol Exp Ther* 1975;193:246–55. [PubMed: 1133767]
30. Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological dependence on plasma tryptophan levels. *Science* 1971;173:149–52. [PubMed: 5581909]
31. Cansev, M.; Wurtman, RJ. Aromatic amino acids in the brain. In: Lajtha, Abel, editor. *Handbook of Neurochemistry and Molecular Neurobiology*. 3rd ed.. 6. Springer Verlag; Berlin-Heidelberg: 2007. p. 6.59-6.97.
32. Farber SA, Savci V, Wei A, Slack BE, Wurtman RJ. Choline's phosphorylation in rat striatal slices is regulated by the activity of cholinergic neurons. *Brain Res* 1996;723:90–9. [PubMed: 8813385]
33. Ulus IH, Watkins CJ, Cansev M, Wurtman RJ. Cytidine and uridine increase striatal CDP-Choline levels without decreasing acetylcholine synthesis or release. *Cell Mol Neurobiol* 2006;26:563–77. [PubMed: 16636900]
34. Maire J-C, Wurtman RJ. Effects of electrical stimulation and choline availability on the release and contents of acetylcholine and choline in superfused slices from rat striatum. *J Physiol* 1985;80:189–95.
35. Blusztajn JK, Holbrook PG, Lakher M, Liscovitch M, Maire JC, Mauron C, Richardson UI, Tacconi M, Wurtman RJ. “Autocannibalism” of membrane cholinephospholipids: physiology and pathology. *Psychopharmacol Bull* 1986;22:781–6. [PubMed: 3025910]
36. Ulus IH, Wurtman RJ, Mauron C, Blusztajn JK. Choline increases acetylcholine release and protects against the stimulation-induced decrease in phosphatide levels within membranes of rat corpus striatum. *Brain Res* 1989;484:217–27. [PubMed: 2713682]
37. Wilgram GF, Kennedy EP. Intracellular distribution of some enzymes catalyzing reactions in the biosynthesis of complex lipids. *J Biol Chem* 1963;238:2615–9. [PubMed: 14063281]
38. Tronchere H, Record M, Terce F, Chap H. Phosphatidylcholine cycle and regulation of phosphatidylcholine biosynthesis by enzyme translocation. *Biochim Biophys Acta* 1994;1212:137–51. [PubMed: 8180240]
39. Sleight R, Kent C. Regulation of phosphatidylcholine biosynthesis in cultured chick embryonic muscle treated with phospholipase C. *J Biol Chem* 1980;255:10644–650. [PubMed: 6253483]
40. Sleight R, Kent C. Regulation of phosphatidylcholine biosynthesis in mammalian cells. I. Effects of phospholipase C treatment on phosphatidylcholine metabolism in Chinese hamster ovary cells and LM mouse fibroblasts. *J Biol Chem* 1983;258:824–30. [PubMed: 6296084]
41. Pelech SL, Cook HW, Paddon HB, Vance DE. Membrane-bound CTP:phosphocholine cytidyltransferase regulates the rate of phosphatidylcholine synthesis in HeLa cells treated with unsaturated fatty acids. *Biochim Biophys Acta* 1984;795:433–40. [PubMed: 6089903]
42. Cornell RB, Northwood IC. Regulation of CTP:phosphocholine cytidyltransferase by amphitropism and relocalization. *Trends Biochem Sci* 2000;25:441–7. [PubMed: 10973058]

43. Utal AK, Jamil H, Vance DE. Diacylglycerol signals the translocation of CTP:choline-phosphate cytidylyltransferase in HeLa cells treated with 12-O-tetradecanoylphorbol-13-acetate. *J Biol Chem* 1991;266:24084–91. [PubMed: 1660890]
44. Weinhold PA, Charles L, Rounsifer ME, Feldman DA. Control of phosphatidylcholine synthesis in Hep G2 cells. Effect of fatty acids on the activity and immunoreactive content of choline phosphate cytidylyltransferase. *J Biol Chem* 1991;266:6093–100. [PubMed: 1848848]
45. Watkins JD, Kent C. Regulation of CTP:phosphocholine cytidylyltransferase activity and subcellular location by phosphorylation in Chinese hamster ovary cells. The effect of phospholipase C treatment. *J Biol Chem* 1991;266:21113–7. [PubMed: 1657950]
46. Mages F, Rey C, Fonlupt P, Pacheco H. Kinetic and biochemical properties of CTP:choline-phosphate cytidylyltransferase from the rat brain. *Eur J Biochem* 1988;178:367–72. [PubMed: 2850176]
47. Mandel P, Edel-Harth S. Free nucleotides in the rat brain during post-natal development. *J Neurochem* 1966;13:591–5. [PubMed: 5939734]
48. Abe K, Koqure K, Yamamoto H, Imazawa M, Miyamoto K. Mechanism of arachidonic acid liberation during ischemia in gerbil cerebral cortex. *J Neurochem* 1987;48:503–9. [PubMed: 3794719]
49. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. *Proc Natl Acad Sci USA* 1992;89:1671–5. [PubMed: 1311847]
50. Choy PC, Paddon HB, Vance DE. An increase in cytoplasmic CTP accelerates the reaction catalyzed by CTP:phosphocholine cytidylyltransferase in poliovirus-infected HeLa cells. *J Biol Chem* 1980;255:1070–3. [PubMed: 6243290]
51. Lopez G-Coviella I, Wurtman RJ. Enhancement by cytidine of membrane phospholipid synthesis. *J Neurochem* 1992;59:338–43. [PubMed: 1613510]
52. Richardson UI, Watkins CJ, Pierre C, Ulus IH, Wurtman RJ. Stimulation of CDP-choline synthesis by uridine or cytidine in PC12 rat pheochromocytoma cells. *Brain Res* 2003;971:161–7. [PubMed: 12706232]
53. Savci V, Wurtman RJ. Effect of cytidine on membrane phospholipid synthesis in rat striatal slices. *J Neurochem* 1995;64:378–84. [PubMed: 7798935]
54. Coleman R, Bell RML. Phospholipid synthesis in isolated fat cells. Studies of microsomal diacylglycerol cholinephosphotransferase and diacylglycerol ethanolaminephosphotransferase activities. *J Biol Chem* 1977;252:3050–6. [PubMed: 192727]
55. Kanoh H, Ohno K. Solubilization and purification of rat liver microsomal 1,2-diacylglycerol: CDP-choline cholinephosphotransferase and 1,2-diacylglycerol: CDP-ethanolamine ethanolaminephosphotransferase. *Eur J Biochem* 1976;66:201–10. [PubMed: 182489]
56. Ishidate K, Matsuo R, Nakazawa Y. CDP-choline:1,2-diacylglycerol cholinephosphotransferase from rat liver microsomes. I. Solubilization and characterization of the partially purified enzyme and the possible existence of an endogenous inhibitor. *Lipids* 1993;28:89–96. [PubMed: 8382767]
57. Roberti R, Vecchini A, Freysz L, Masoom M, Binaglia L. An improved procedure for the purification of ethanolaminephosphotransferase. Reconstitution of the purified enzyme with lipids. *Biochim Biophys Acta* 1989;1004:80–8. [PubMed: 2545264]
58. O K-M, Choy PC. Solubilization and partial purification of cholinephosphotransferase in hamster tissues. *Lipids* 1990;25:122–4. [PubMed: 2158610]
59. Henneberry AL, McMaster CR. Cloning and expression of a human choline/ethanolaminephosphotransferase: synthesis of phosphatidylcholine and phosphatidylethanolamine. *Biochem J* 1999;339:291–8. [PubMed: 10191259]
60. Henneberry AL, Wistow G, McMaster CR. Cloning, genomic organization, and characterization of a human cholinephosphotransferase. *J Biol Chem* 2000;275:29808–15. [PubMed: 10893425]
61. Kanoh H, Ohno K. Utilization of endogenous phospholipids by the backreaction of CDP-choline (-ethanolamine): 1,2-diglyceride choline (ethanolamine)-phosphotransferase in rat liver microsomes. *Biochim Biophys Acta* 1973;306:207–17.
62. Kanoh H, Ohno K. Studies on 1,2-diglycerides formed from endogenous lecithins by the back-reaction of rat liver microsomal cdpcholine: 1,2-diacylglycerol cholinephosphotransferase. *Biochim Biophys Acta* 1973;326:17–25. [PubMed: 4756118]

63. Goracci G, Francescangeli E, Horrocks LA, Porcelatti G. The reverse reaction of cholinephosphotransferase in rat brain microsomes. A new pathway for degradation of phosphatidylcholine. *Biochim Biophys Acta* 1981;664:373–9. [PubMed: 6264965]
64. Goracci G, Francescangeli E, Horrocks LA, Porcelatti G. A comparison of the reversibility of phosphoethanolamine transferase and phosphocholine transferase in rat brain microsomes. *Biochim Biophys Acta* 1986;876:387–91. [PubMed: 3011101]
65. Roberti R, Mancini A, Freysz L, Binaglia L. Reversibility of the reactions catalyzed by cholinephosphotransferase and ethanolaminephosphotransferase solubilized from rat-brain microsomes. *Biochim Biophys Acta* 1992;1165:183–8. [PubMed: 1333282]
66. Cornell RB. Cholinephosphotransferase from mammalian sources. *Methods Enzymol* 1992;209:267–72. [PubMed: 1323041]
67. Korniat EK, Beeler DA. Water-soluble phospholipid precursor pool-sizes in quick-frozen and unfrozen rat livers. *Anal Biochem* 1975;69:300–5. [PubMed: 1211633]
68. Turinsky J, Bayly BP, O'Sullivan DM. 1,2-diacylglycerol and ceramide levels in rat liver and skeletal muscle in vivo. *Am J Physiol* 1991;261:E620–7. [PubMed: 1951687]
69. Alberghina M, Viola M, Giuffrida AM. Pool size of CDP-choline in the brain, heart, and lung of normal hypoxic guinea pigs. *J Neurosci Res* 1981;6:719–22. [PubMed: 7334532]
70. Jamil H, Udal AK, Vance DE. Evidence that cyclic AMP-induced inhibition of phosphatidylcholine biosynthesis is caused by a decrease in cellular diacylglycerol levels in cultured rat hepatocytes. *J Biol Chem* 1992;267:1752–60. [PubMed: 1309795]
71. Wright MM, McMaster CR. PC and PE synthesis: mixed micellar analysis of the cholinephosphotransferase and ethanolaminephosphotransferase activities of human choline/ethanolamine phosphotransferase 1 (CEPT1). *Lipids* 2002;37:663–72. [PubMed: 12216837]
72. Mantel CR, Schultz AR, Miyazawa K, Broxmeyer HE. Kinetic selectivity of cholinephosphotransferase in mouse liver: the K_m for CDP-choline depends on diacylglycerol structure. *Biochem J* 1993;289:815–20. [PubMed: 8382052]
73. Richardson UI, Wurtman RJ. Polyunsaturated fatty acids regulate phosphatidylcholine synthesis in PC12 cells. *Biochim Biophys Acta* 2007;1771:558–63. [PubMed: 17350887]
74. Baldwin SA, Beal PR, Yao SYM, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. *Pflugers Arch* 2004;447:735–43. [PubMed: 12838422]
75. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. *Pflugers Arch* 2004;447:728–34. [PubMed: 12856181]
76. Cansev M. Uridine and cytidine in the brain: Their transport and utilization. *Brain Res Brain Res Rev* 2006;52:389–397.
77. Redzic ZB, Biringer J, Barnes K, Baldwin SA, Al-Sarraf H, Nicola PA, Young JD, Cass CE, Barrand MA, Hlandky SB. Polarized distribution of nucleoside transporters in rat brain endothelial and choroid plexus epithelial cells. *J Neurochem* 2005;94:1420–26. [PubMed: 16111480]
78. Murakami H, Ohkura A, Takanaga H, Matsuo H, Koyabu N, Naito M, Tsuruo T, Ohtani H, Sawada Y. Functional characterization of adenosine transport across the BBB in mice. *Int J Pharm* 2005;290:37–44. [PubMed: 15664128]
79. Pastor-Anglada M, Felipe A, Casado FJ. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. *Trends Pharmacol Sci* 1998;19:424–30. [PubMed: 9803833]
80. Li JY, Boado RJ, Pardridge WM. Cloned blood-brain barrier adenosine transporter is identical to the rat concentrative Na^+ nucleoside cotransporter CNT2. *J Cereb Blood Flow Metab* 2001;21:929–36. [PubMed: 11487728]
81. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. *Biochim Biophys Acta* 1996;1286:153–181. [PubMed: 8982282]
82. Traut TW. Physiological concentrations of purines and pyrimidines. *Mol Cell Biochem* 1994;140:1–22. [PubMed: 7877593]
83. Larrayoz IM, Fernandez-Nistal A, Garces A, Gorraitz E, Lostao MP. Characterization of the rat Na^+ /nucleoside cotransporter 2 (rCNT2) and transport of nucleoside-derived drugs using electrophysiological methods. *Am J Physiol Cell Physiol* 2006;291:C1395–404. [PubMed: 16837649]

84. Nagai K, Nagasawa K, Koma M, Hotta A, Fujimoto S. Cytidine is a novel substrate for wild-type concentrative nucleoside transporter 2. *Biochem Biophys Res Commun* 2006;347:439–43. [PubMed: 16828706]
85. Nagai K, Nagasawa K, Koma M, Kihara Y, Fujimoto S. Contribution of an unidentified sodium-dependent nucleoside transport system to the uptake and cytotoxicity of anthracycline in mouse M5076 ovarian sarcoma cells. *Biochem Pharmacol* 2006;71:565–73. [PubMed: 16376308]
86. Cansev M, Wurtman RJ. Exogenous cytidine-5'-diphosphocholine increases brain cytidine-5'-diphosphocholine levels in gerbils. *J Neurochem* 2005;94(Suppl 2):105–6.
87. Anderson CM, Xiong W, Geiger JD, Young JD, Cass CE, Baldwin SA, Parkinson FE. Distribution of equilibrative, nitrobenzylthioinosine-insensitive nucleoside transporters (ENT1) in rat brain. *J Neurochem* 1999;73:867–73. [PubMed: 10428086]
88. Anderson CM, Baldwin SA, Young JD, Cass CE, Parkinson FE. Distribution of mRNA encoding a nitrobenzylthioinosine-insensitive nucleoside transporter (ENT2) in rat brain. *Brain Res Mol Brain Res* 1999;70:293–7. [PubMed: 10407178]
89. Wu X, Yuan G, Brett CM, Hui AC, Giacomini KM. Sodium-dependent nucleoside transport in choroid plexus from rabbit. Evidence for a single transporter for purine and pyrimidine nucleosides. *J Biol Chem* 1992;267:8813–8. [PubMed: 1315741]
90. Wu X, Gutierrez MM, Giacomini KM. Further characterization of the sodium-dependent nucleoside transporter (N3) in choroid plexus from rabbit. *Biochim Biophys Acta* 1994;1191:190–6. [PubMed: 8155674]
91. Pardridge, WM. Invasive brain drug delivery. In: Pardridge, WM., editor. *Brain Drug Targeting: The Future of Brain Drug Development*. 1st ed.. Cambridge University Press; Cambridge, UK: 2001. p. 13-35.
92. Canellakis ES. Pyrimidine metabolism. II. Enzymatic pathways of uracil anabolism. *J Biol Chem* 1957;227:329–38. [PubMed: 13449076]
93. Skold O. Uridine kinase from Erlich ascites tumor: Purification and properties. *J Biol Chem* 1960;235:3273–9.
94. Orengo A. Regulation of enzymic activity by metabolites. I. Uridine-cytidine kinase of Novikoff ascites rat tumor. *J Biol Chem* 1969;244:2204–9. [PubMed: 5782006]
95. Balestri F, Barsotti C, Lutzemberger L, Camici M, Ipata PL. Key role of uridine kinase and uridine phosphorylase in the homeostatic regulation of purine and pyrimidine salvage in brain. *Neurochem Int*. In Press
96. Krystal G, Webb TE. Multiple forms of uridine kinase in normal and neoplastic rat liver. *Biochem J* 1971;124:943–7. [PubMed: 4331862]
97. Absil J, Tuilie M, Roux J-M. Electrophoretically distinct forms of uridine kinase in the rat. Tissue distribution and age-dependence. *Biochem J* 1980;185:273–6. [PubMed: 6246878]
98. Koizumi K, Shimamoto Y, Azuma A, Wataya Y, Matsuda A, Sasaki T, Fukushima M. Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells. *Int J Mol Med* 2001;8:273–8. [PubMed: 11494055]
99. Van Rompay AR, Norda A, Linden K, Johansson M, Karlsson A. Phosphorylation of uridine and cytidine analogs by two human uridine-cytidine kinases. *Mol Pharmacol* 2001;59:1181–6. [PubMed: 11306702]
100. Hurwitz J. The enzymatic incorporation of ribonucleotides into polydeoxynucleotide material. *J Biol Chem* 1959;234:2351–8. [PubMed: 14405566]
101. Sugino Y, Teraoka H, Shimono H. Metabolism of deoxyribonucleotides. I. Purification and properties of deoxycytidine monophosphokinase of calf thymus. *J Biol Chem* 1966;241:961–9. [PubMed: 5905133]
102. Ruffner BW, Anderson EP. Adenosine triphosphate: uridine monophosphate:cytidine monophosphate phosphotransferase from *Tetrahymena pyriformis*. *J Biol Chem* 1969;244:5994–6002. [PubMed: 5350952]
103. Berg P, Joklik WK. Enzymatic phosphorylation of nucleoside diphosphates. *J Biol Chem* 1954;210:657–72. [PubMed: 13211603]
104. Parks, RE., Jr; Agarwal, RP. Nucleoside diphosphokinases. In: Boyer, PD., editor. *The Enzymes*. Academic Press; New York: 1973. p. 307-33.

105. Van Rompay AR, Johansson M, Karlsson A. Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: Molecular characterization of the human enzyme. *Mol Pharmacol* 1999;56:562–9. [PubMed: 10462544]
106. Langen H, Berndt P, Roder D, Cairns N, Lubec G, Fountoulakis M. Two dimensional map of human brain proteins. *Electrophoresis* 1999;20:907–16. [PubMed: 10344266]
107. Kim SH, Fountoulakis M, Cairns NJ, Lubec G. Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. *Biochem Biophys Res Commun* 2002;296:970–5. [PubMed: 12200143]
108. Wang TP, Sable HZ, Lampen JO. Enzymatic deamination of cytosine nucleosides. *J Biol Chem* 1950;184:17–28. [PubMed: 15421968]
109. Lieberman I. Enzymatic amination of uridine triphosphate to cytidine triphosphate. *J Biol Chem* 1956;222:765–75. [PubMed: 13367044]
110. Hurlbert RB, Kammen HO. Formation of cytidine nucleotides from uridine nucleotides by soluble mammalian enzymes: Requirements for glutamine and guanosine nucleotides. *J Biol Chem* 1960;235:443–9.
111. Zalkin H. CTP synthase. *Methods Enzymol* 1985;113:282–7. [PubMed: 3911002]
112. Genchev DD, Mandel P. CTP synthetase activity in neonatal and adult rat brain. *J Neurochem* 1974;22:1027–30. [PubMed: 4851257]
113. Anderson, EP. Nucleoside and nucleotide kinases. In: Boyer, PD., editor. *The Enzymes*. Academic Press; New York: 1973. p. 49-96.
114. Greenberg N, Schumm DE, Webb TE. Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma. *Biochem J* 1977;164:379–87. [PubMed: 195585]
115. Ropp PA, Traut TW. Cloning and expression of a cDNA encoding uridine kinase from mouse brain. *Arch Biochem Biophys* 1996;336:105–12. [PubMed: 8951040]
116. Ropp PA, Traut TW. Uridine kinase: Altered enzyme with decreased affinities for uridine and CTP. *Arch Biochem Biophys* 1998;359:63–8. [PubMed: 9799561]
117. Mascia L, Cotrufo T, Cappiello M, Ipata PL. Ribose 1-phosphate and inosine activate uracil salvage in rat brain. *Biochim Biophys Acta* 1999;1472:93–8. [PubMed: 10572929]
118. Peters GJ, van Groenigen CJ, Laurensse EJ, Lankelma J, Leyva A, Pinedo HM. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. *Cancer Chemother Pharmacol* 1987;20:101–8. [PubMed: 3664929]
119. Kamp F, Westerhoff HV, Hamilton JA. Movement of fatty acids, fatty acid analogues, and bile acids across phospholipid bilayers. *Biochemistry* 1993;32:11074–86. [PubMed: 8218171]
120. Abumrad NA, Park JH, Park CR. Permeation of long-chain fatty acid into adipocytes. Kinetics, specificity, and evidence for involvement of a membrane protein. *J Biol Chem* 1984;259:8945–53. [PubMed: 6746632]
121. Chmurzynska A. The multigene family of fatty acid-binding proteins: Function, structure and polymorphism. *J Appl Genet* 2006;47:39–48. [PubMed: 16424607]
122. Shimizu F, Watanabe TK, Shinomiya H, Nakamura Y, Fujiwara T. Isolation and expression of a cDNA for human brain fatty acid-binding protein (B-FABP). *Biochim Biophys Acta* 1997;1354:24–8. [PubMed: 9375786]
123. Robinson PJ, Noronha J, DeGeorge JJ, Freed LM, Nariai T, Rapoport SI. A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: review and critical analysis. *Brain Res Brain Res Rev* 1992;17:187–214. [PubMed: 1467810]
124. Bazan, NG. Supply of n-3 polyunsaturated fatty acids and their significance in the central nervous system. In: Wurtman, RJ.; Wurtman, JJ., editors. *Nutrition and the Brain*. 1st ed.. 8. Raven Press; New York, NY: 1990. p. 8.1-8.24.
125. Thies F, Pillon C, Moliere P, Lagarde M, Lecerf J. Preferential incorporation of sn-2 lysoPC DHA over unesterified DHA in the young rat brain. *Am J Physiol* 1994;267:R1273–9. [PubMed: 7977854]
126. Marszalek JR, Kitidis C, DiRusso CC, Lodish HF. Long-chain acyl-CoA synthetase 6 preferentially promotes DHA metabolism. *J Biol Chem* 2005;280:10817–26. [PubMed: 15655248]

127. Reddy TS, Sprecher P, Bazan NG. Long-chain acyl-coenzyme A synthetase from rat brain microsomes. Kinetic studies using [1-¹⁴C]docosahexaenoic acid substrate. *Eur J Biochem* 1984;145:21–9. [PubMed: 6237910]
128. Contreras MA, Greiner RS, Chang MC, Myers CS, Salem N Jr, Rapoport SI. Nutritional deprivation of alpha-linolenic acid decreases but does not abolish turnover and availability of unacylated docosahexaenoic acid and docosahexaenoyl-CoA in rat brain. *J Neurochem* 2000;75:2392–400. [PubMed: 11080190]
129. Neufeld EJ, Wilson DB, Sprecher H, Majerus PW. High affinity esterification of eicosanoid precursor fatty acids by platelets. *J Clin Invest* 1983;72:214–20. [PubMed: 6308046]
130. Moore SA, Yoder A, Murphy S, Dutton GR, Spector AA. Astrocytes, not neurons, produce docosahexaenoic acid (22:6w-3) and arachidonic acid (20:4w-6). *J Neurochem* 1991;56:518–24. [PubMed: 1824862]
131. DeGeorge JJ, Nariai T, Yamazaki S, Williams WM, Rapoport SI. Arecoline-stimulated brain incorporation of intravenously administered fatty acids in unanesthetized rats. *J Neurochem* 1991;56:352–5. [PubMed: 1824784]
132. Sarda N, Gharib A, Moliere P, Grange E, Bobillier P, Lagarde M. Docosahexaenoic acid (cervonic acid) incorporation into different brain regions in the awake rat. *Neurosci Lett* 1991;123:57–60. [PubMed: 1829511]
133. Farooqui AA, Horrocks LA. Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue. *J Mol Neurosci* 2001;16:263–272. [PubMed: 11478381]
134. Nagan N, Zoeller RA. Plasmalogens: biosynthesis and functions. *Prog Lipid Res* 2001;40:199–29. [PubMed: 11275267]
135. O'Brien JS, Sampson EL. Fatty acid and fatty aldehyde composition of the major brain lipids in normal human gray matter, white matter, and myelin. *J Lipid Res* 1965;6:545–51. [PubMed: 5865383]
136. Breckenridge WC, Gombos G, Morgan IG. The lipid composition of adult rat brain synaptosomal plasma membranes. *Biochim Biophys Acta* 1972;266:695–707. [PubMed: 4339171]
137. Svennerholm L. Distribution and fatty acid composition of phosphoglycerides in normal human brain. *J Lipid Res* 1968;9:570–9. [PubMed: 4302302]
138. Hicks AM, DeLong CJ, Thomas MJ, Samuel M, Cui Z. Unique molecular signatures of glycerophospholipid species in different rat tissues analyzed by tandem mass spectrometry. *Biochim Biophys Acta* 2006;1761:1022–9. [PubMed: 16860597]
139. Carlier H, Bernard A, Caselli C. Digestion and absorption of polyunsaturated fatty acids. *Reprod Nutr Dev* 1991;31:475–500. [PubMed: 1768307]
140. Bezard J, Blond JP, Bernard A, Clouet P. The metabolism and availability of essential fatty acids in animal and human tissues. *Reprod Nutr Dev* 1994;34:539–68. [PubMed: 7840871]
141. Rapoport SI, Chang MCJ, Spector AA. Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. *J Lipid Res* 2001;42:678–85. [PubMed: 11352974]
142. Philbrick DJ, Mahadevappa VG, Ackman RG, Holub BJ. Ingestion of fish oil or a derived n-3 fatty acid concentrate containing eicosapentaenoic acid (EPA) affects fatty acid compositions of individual phospholipids of rat brain, sciatic nerve and retina. *J Nutr* 1987;117:1663–70. [PubMed: 2822876]
143. Pawlosky RJ, Hibbeln JR, Novotny JA, Salem N Jr. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. *J Lipid Res* 2001;42:1257–65. [PubMed: 11483627]
144. Zhou L, Vessby B, Nilsson A. Quantitative role of plasma free fatty acids in the supply of arachidonic acid to extrahepatic tissues in rats. *J Nutr* 2002;132:2626–31. [PubMed: 12221221]
145. Rapoport SI. In vivo approaches and rationale for quantifying kinetics and imaging brain lipid metabolic pathways. *Prostaglandins Other Lipid Mediat* 2005;77:185–96. [PubMed: 16099403]
146. Strokin M, Sergeeva M, Reiser G. Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A2 and is differently regulated by cyclic AMP and Ca²⁺. *British J Pharmacol* 2003;139:1014–22.
147. Teng FYH, Wang Y, Tang BL. The syntaxins. *Genome Biol* 2001;2:3012–17.

148. Kothapalli KSD, Anthony JC, Pan BS, Hsieh AT, Nathanielsz PW, Brenna JT. Differential cerebral cortex transcriptomes of baboon neonates consuming moderate and high docosahexaenoic acid formulas. *PLoS ONE* 2007;2:e370. [PubMed: 17426818]
149. Lands WEM, Inoue M, Sugiura Y, Okuyama H. Selective incorporation of polyunsaturated fatty acids into phosphatidylcholine by rat liver microsomes. *J Biol Chem* 1982;257:14968–72. [PubMed: 7174678]
150. Matus A. Actin-based plasticity in dendritic spines. *Science* 2000;290:754–8. [PubMed: 11052932]
151. Hering H, Sheng M. Dendritic spines: structure, dynamics and regulation. *Nat Rev Neurosci* 2001;2:880–8. [PubMed: 11733795]
152. Nimchinsky EA, Sabatini BL, Svoboda K. Structure and function of dendritic spines. *Annu Rev Physiol* 2002;64:313–53. [PubMed: 11826272]
153. El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Brecht DS. PSD-95 involvement in maturation of excitatory synapses. *Science* 2000;290:1364–8. [PubMed: 11082065]
154. Kasai H, Matsuzaki M, Noguchi J, Yasumatsu N, Nakahara H. Structure-stability-function relationships of dendritic spines. *Trends Neurosci* 2003;26:360–8. [PubMed: 12850432]
155. Matsuzaki M, Honkura N, Ellis-Davies GC, Kasai H. Structural basis of long-term potentiation in single dendritic spines. *Nature* 2004;429:761–6. [PubMed: 15190253]
156. Greengard P, Valtorta F, Czernik AJ, Benfenati F. Synaptic vesicle phosphoproteins and regulation of synaptic function. *Science* 1993;259:780–5. [PubMed: 8430330]
157. Ziv NE, Garner CC. Cellular and molecular mechanisms of presynaptic assembly. *Nat Rev Neurosci* 2004;5:385–99. [PubMed: 15100721]
158. Matus A. Growth of dendritic spines: a continuing story. *Curr Opin Neurobiol* 2005;15:67–72. [PubMed: 15721746]
159. Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine 5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Submitted for Publication
160. Williams JH, Errington ML, Lynch MA, Bliss TVP. Arachidonic acid induces a long-term activity-dependent enhancement of synaptic transmission in the hippocampus. *Nature* 1989;341:739–42. [PubMed: 2571939]
161. Ramakers GM, Storm JFA. Postsynaptic transient K(+) current modulated by arachidonic acid regulates synaptic integration and threshold for LTP induction in hippocampal pyramidal cells. *Proc Natl Acad Sci USA* 2002;99:10144–9. [PubMed: 12114547]
162. Feinmark SJ, Begum R, Tsvetkov E, Goussakov I, Funk CD, Siegelbaum SA, Bolshakov VY. 12-lipoxygenase metabolites of arachidonic acid mediate metabotropic glutamate receptor-dependent long-term depression at hippocampal CA3-CA1 synapses. *J Neurosci* 2003;23:11427–35. [PubMed: 14673007]
163. Ikemoto A, Kobayashi T, Watanabe S, Okuyama H. Membrane fatty acid modifications of PC12 cells by arachidonate or docosahexaenoate affect neurite outgrowth but not norepinephrine release. *Neurochem Res* 1997;22:671–8. [PubMed: 9178949]
164. Calderon F, Kim H-Y. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. *J Neurochem* 2004;90:979–88. [PubMed: 15287904]
165. Wang L, Pooler AM, Albrecht MA, Wurtman RJ. Dietary uridine-5'-monophosphate supplementation increases potassium-evoked dopamine release and promotes neurite outgrowth in aged rats. *J Mol Neurosci* 2005;27:137–45. [PubMed: 16055952]
166. Wang L, Albrecht MA, Wurtman RJ. Dietary supplementation with uridine-5'-monophosphate (UMP), a membrane phosphatide precursor, increases acetylcholine level and release in striatum of aged rat. *Brain Res* 2007;1133:42–8. [PubMed: 17184749]
167. Abbracchio MP, Burnstock G, Boeynaems J-M, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. *Pharmacol Rev* 2006;58:281–341. [PubMed: 16968944]
168. Price GD, Robertson SJ, Edwards FA. Long-term potentiation of glutamatergic synaptic transmission induced by activation of presynaptic P2Y receptors in the rat medial habenula nucleus. *Eur J Neurosci* 2003;17:844–50. [PubMed: 12603274]

169. Yuste R, Bonhoeffer T. Genesis of dendritic spines: insights from ultrastructural and imaging studies. *Nat Rev Neurosci* 2004;5:24–34. [PubMed: 14708001]
170. Teather LA, Wurtman RJ. Chronic administration of UMP ameliorates the impairment of hippocampal-dependent memory in impoverished rats. *J Nutr* 2006;136:2834–7. [PubMed: 17056809]

Figure 1.
Structure of phosphatidylcholine

Figure 2.

Phosphatidylcholine (PC) biosynthesis via the Kennedy cycle [17]. In rats, cytidine is the major circulating pyrimidine [95]; in humans [19] and gerbils [20] the primary circulating pyrimidine is uridine. Only small amounts of circulating cytidine are converted to brain CTP, since the blood-brain barrier (BBB) high-affinity transporter for pyrimidines (CNT2) has a very low affinity for cytidine [96-98]; uridine, in contrast, readily enters the brain via CNT2, yielding UTP which can be converted to CTP by CTP synthase [89]. CTP then reacts with phosphocholine to form CDP-choline, which combines with diacylglycerol (DAG), preferentially species containing PUFAs like DHA, EPA or AA to form PC. Boxes indicate the compounds that are obtained from the circulation. Synthesis of PE via the Kennedy cycle utilizes ethanolamine instead of choline. (From Cansev M and Wurtman RJ, In Press)

Figure 3.

Effects of AA, DHA or EPA, alone or in combination with a UMP-supplemented diet, on levels of the pre- or postsynaptic proteins PSD-95 (a1, a2); Synapsin-1 (b1, b2) and Syntaxin-3 (c1, c2). CV, control diet + vehicle; CA, control diet + AA; CD, control diet + DHA; CE, control diet + EPA; UV, UMP-supplemented diet + vehicle; UA, UMP-supplemented diet + AA; UD, UMP-supplemented diet + DHA; UE, UMP-supplemented diet + EPA. * $P < 0.05$; ** $P < 0.01$; and *** $P < 0.001$ compared with CV, and ^a $P < 0.05$ compared with CA on the left-sided columns (a1, b1, and c1) using One Way ANOVA. * $P < 0.05$; ** $P < 0.01$; and *** $P < 0.001$ compared with UV, and ^y $P < 0.01$ compared with UA on the right-sided columns (a2, b2, and c2) using One Way ANOVA. (From Cansev M and Wurtman RJ, In Press)

Figure 4.

Effects of DHA on brain CDP-choline or CDP-ethanolamine levels. Groups of 8 gerbils received either a control or a UMP-containing (0.5%) diet and, by gavage, DHA (300 mg/kg; in a vehicle of 5% gum Arabic solution) or just its vehicle, for 28 days. On the 29th day their brains were harvested and assayed for A) CDP-choline or B) CDP-ethanolamine. ^aP<0.05 and ^cP<0.01 when compared with the values for control diet plus vehicle group; ^bP<0.05 when compared with values for UMP diet plus vehicle group. (From Wurtman RJ et al., Brain Research, 2006; 1088: 83-92)

Figure 5.

Effects of DHA, alone or in combination with a UMP-supplemented diet, on dendritic spine formation in adult gerbil hippocampus. Animals received UMP (0.5%), DHA (300 mg/kg) or both daily for 4 weeks; control gerbils received neither. (A) Apical dendrites of CA1 pyramidal neurons. (B) Animals supplemented with DHA exhibited a significant increase in spine density (by 19%, * $P = .004$ vs. Control); those receiving both DHA and UMP exhibited a greater increase (by 36%, ** $P < .001$ vs. Control or by 17%, $p = .008$ vs. DHA). $n = 20 \sim 25$ neurons from 4 animals per group. One-way ANOVA followed by Tukey's test. (C) The effect of DHA-plus-UMP on spine density was apparent by 1 week after the start of the treatment. The treated groups received both UMP (0.5%) and DHA (300 mg/kg) daily for 1, 2, 3 or 4 weeks; the

control groups were given only a regular diet. $n = 12 \sim 20$ neurons from 2 animals per group. Two-way ANOVA followed by Tukey's test. $*P = .02$; $**P < .001$. (From Sakamoto T et al., Submitted for Publication)

Figure 6.

Effects of oral supplementation with various doses of DHA on dendritic spine density in adult gerbil hippocampus. Animals were supplemented with 0, 50, 100 or 300 mg/kg of DHA daily for 4 weeks. (A) Apical dendrites of CA1 pyramidal neurons. (B) Animals supplemented with 100 or 300 mg/kg/day showed increased spine density: a 12 % increase after the 100 mg/kg/day dose (* $P = .04$) and an 18 % increase after the 300 mg/kg/day dose (** $P < .001$ vs. 0 mg/kg/day). $n = 16 \sim 20$ neurons from 2 animals per group. (From Sakamoto T et al., Submitted for Publication)

Figure 7.

Rats were allowed to eat 16 % protein chow, or the same diet supplemented with 0.5% UMP and /or by gavage 300 mg/kg DHA. Rats began to eat the UMP-supplemented chow, and to receive the daily gavage of DHA, at approximately 4 weeks of age, 4 weeks prior to testing in a water maze, which continued throughout testing. Also beginning at 4 weeks of age and continuing for a duration of 4 weeks, rats were placed in impoverished conditions (IC). IC required that rats be housed individually without toys, and exercised 3 times a week for 15 minutes in an empty room to avoid weight gain. Following exposure to 4 weeks of impoverished environmental conditions, rats' learning and memory was tested using the hidden version of the Morris water maze. (8 animals in each group). (From Holguin S et al., Submitted for Publication)

Table 1

Effects of UMP-containing diet and/or DHA on brain phospholipid levels.

Treatments	Total PL	PC	PE	SM	PS	PI
Control diet + Vehicle	351	152	65	45	33	21
UMP diet + Vehicle	367	171*	84*	52	35	31**
Control diet + DHA	392	185*	78*	56*	39	32**
UMP diet + DHA	442***	220***	113***	73***	46***	36***

Groups of 8 gerbils were given either a control or a UMP-containing (0.5%) diet, and received orally (by gavage) DHA (300 mg/kg; in a vehicle of 5% gum Arabic solution) or just its vehicle for 28 days. On the 29th day their brains were harvested and assayed for phospholipids.

Data are presented as nmol/mg protein. (From Wurtman RJ et al., Brain Research, 2006; 1088: 83-92)

* P<0.05
** P<0.01
*** P<0.001 compared with values from Control diet + Vehicle group.

Table 2
Effects of various PUFA, given with a control diet (Table 2A) or a UMP-supplemented diet (Table 2B), on gerbil brain phosphatide levels.

Table 2A	Total PL	PC	PE	PS	PI
Control diet + Vehicle	322	113	63	251	15
Control diet + AA	326	114	65	281	16
Control diet + DHA	344	133*	77*	32***	18*
Control diet + EPA	347	125	76*	31**	19,***
#UMP diet + Vehicle	332	131*	701	29*	16
Table 2B	Total PL	PC	PE	PS	PI
UMP diet + Vehicle	332	131	70	29	16
UMP diet + AA	379	132	81	31	20
UMP diet + DHA	384*	147,***	88***	39**	22**
UMP diet + EPA	407***	148,***	91***	41,***	25***

Groups of gerbils were given a control diet, and received by gavage AA, DHA, or EPA (each 300 mg/kg; in a vehicle of 5% gum Arabic solution) or just its vehicle for 28 days. On the 29th day their brains were harvested and assayed for phosphatides as described in the text. Data are given as means ± SEM.

Data are presented as nmol/mg protein.

Groups of gerbils were given a UMP-containing (0.5%) diet, and received by gavage AA, DHA, or EPA (each 300 mg/kg; in a vehicle of 5% gum Arabic solution) or just its vehicle for 28 days. On the 29th day their brains were harvested and assayed for phosphatides as described in the text. Data are given as means ± SEM.

* P<0.05

** P<0.01

*** P<0.001 compared to Control diet + Vehicle group

^a P<0.05 compared to Control diet + AA group by One Way ANOVA.

[#] Data from gerbils receiving the UMP diet but no PUFA are included in Table 2A to illustrate that uridine alone also affects phosphatide levels.

* P<0.05

** P<0.01

*** P<0.001 compared to Control diet + Vehicle group

^x P<0.05

^y P<0.01 compared to UMP diet + AA group by One Way ANOVA. (From Cansev M and Wurtman RJ, In Press)

Table 3
Effects of giving UMP-supplemented diet (0.5%) and DHA (300 mg/kg) on phosphatide levels in different gerbil brain regions.

	Cortex	Striatum	Hippocampus	Brain Stem	Cerebellum
Total PL					
Control diet + Vehicle	267	265	264	450	270
UMP diet + DHA	316**	339***	314**	521**	317**
PC					
Control diet + Vehicle	94	100	102	114	98
UMP diet + DHA	122***	126*	117***	139***	111***
PE					
Control diet + Vehicle	58	60	61	117	64
UMP diet + DHA	80**	85***	81***	156***	85***
PS					
Control diet + Vehicle	24	24	24	30	24
UMP diet + DHA	30***	29*	28***	35***	29**
PI					
Control diet + Vehicle	10.6	7.6	8.8	9.3	10.4
UMP diet + DHA	13.2**	11.9***	11***	11.8*	11.5*

Groups of gerbils were given a UMP-containing (0.5%) diet and, received by gavage, DHA (300 mg/kg; in a vehicle of 5% gum Arabic solution) or just the vehicle, for 28 days. On the 29th day various brain regions were harvested and assayed for phosphatides as described in the text. Data are presented as nmol/mg protein.

* P<0.05

** P<0.01

*** P<0.001

P<0.001 compared to Control diet + Vehicle group using Student's t test. (From Cansev M and Wurtman RJ, In Press)